Physician profile
Claude B Romulus
NPI 1609818277
$574.73
in general payments reported to CMS, 2019-2025
15 companies · $19.23 in 2025
The $19.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.34 · 2020: $69.25 · 2021: $191 · 2022: $116 · 2023: $43.74 · 2024: $67.24 · 2025: $19.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $88.11 | 2022-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $74.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $35.39 | 2020-2021 | |
| Horizon Therapeutics Plc | $34.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.68 | 2021-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $28.25 | 2024 | Voquezna |
| Abbott Laboratories | $22.25 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.13 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.40 | 2021 | |
| Exact Sciences Corporation | $19.23 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $18.68 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Romulus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.